{
    "clinical_study": {
        "@rank": "149664", 
        "acronym": "PAA 12-01", 
        "arm_group": {
            "arm_group_label": "Popliteal aneurysm", 
            "description": "GORE\u00ae VIABAHN\u00ae Endoprosthesis used to treat popliteal aneurysm"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, non-randomized, single arm, retrospective study of GORE\u00ae VIABAHN\u00ae\n      Endoprosthesis for the treatment of a Popliteal Artery Aneurysm (PAA)."
        }, 
        "brief_title": "Evaluation of GORE\u00ae VIABAHN\u00ae Endoprosthesis for Popliteal Artery Aneurysm", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Popliteal Artery Aneurysm", 
        "condition_browse": {
            "mesh_term": "Aneurysm"
        }, 
        "detailed_description": {
            "textblock": "The primary objective is to evaluate the safety and efficacy of the GORE\u00ae VIABAHN\u00ae\n      Endoprosthesis for the treatment of subjects with Popliteal Artery Aneurysms. The study\n      population includes subjects with an asymptomatic aneurysm (\u2265 2 cm diameter) of the\n      popliteal artery, symptomatic aneurysm (no diameter requirement) of the popliteal artery, or\n      presence of mural thrombus (no diameter requirement) of the popliteal artery treated with\n      the GORE\u00ae VIABAHN\u00ae Endoprosthesis between January 1, 2002 and December 31, 2010.  Starting\n      with most recently treated within the above date range, patients meeting Inclusion/Exclusion\n      will be enrolled, until a minimum of 50 subjects with adequate follow up to determine\n      primary endpoints through 12 months will be provided."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Received a GORE\u00ae VIABAHN\u00ae Endoprosthesis between January 1, 2002 and December 31,\n             2010 to treat a popliteal artery aneurysm;\n\n          -  Had an asymptomatic aneurysm (\u2265 2 cm diameter) of the popliteal artery, or\n             symptomatic aneurysm (no diameter requirement) of the popliteal artery, or the\n             presence of mural thrombus (no diameter requirement) of the popliteal artery;\n\n          -  Was 18 years of age or older; and\n\n          -  Had an elective popliteal artery aneurysm procedure.\n\n        Exclusion Criteria:\n\n          -  Bilateral popliteal artery aneurysms with initial treatment on the same day\n\n          -  Had previous surgery for the popliteal artery aneurysm in the study limb"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who had popliteam aneurysm and were treated with GORE\u00ae VIABAHN\u00ae Endoprosthesis\n        between January 1, 2002 and  December 31, 2010."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902888", 
            "org_study_id": "PAA 12-01"
        }, 
        "intervention": {
            "arm_group_label": "Popliteal aneurysm", 
            "intervention_name": "GORE\u00ae VIABAHN\u00ae Endoprosthesis", 
            "intervention_type": "Device", 
            "other_name": "Viabahn"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "popliteal artery", 
            "aneurysm", 
            "popliteal artery aneurysm", 
            "asymptomatic aneurysm", 
            "mural thrombus", 
            "Viabahn", 
            "Gore", 
            "Endoprosthesis"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Baptist Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "The Vascular Group of Naples"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Retrospective Evaluation of the GORE\u00ae VIABAHN\u00ae Endoprosthesis for a Popliteal Artery Aneurysm Indication", 
        "overall_official": {
            "affiliation": "W. L. Gore & Associates, Inc (sponsor)", 
            "last_name": "Hector Novoa, BS", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A composite of freedom from failure of technical success or loss of primary patency at 12 months", 
                "measure": "Primary Efficacy Endpoint: The number of patients that do not have a failure of technical success or loss of primary patency.", 
                "safety_issue": "No", 
                "time_frame": "12 months following initial study procedure"
            }, 
            {
                "description": "30 day serious adverse events related to the initial study procedure or the study device.", 
                "measure": "Primary Safety Endpoint: Number of Serious Adverse Events (related to initial procedure or the device itself) that occur within 30 days of the initial study procedure.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days following initial study procedure"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902888"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "W.L.Gore & Associates", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "W.L.Gore & Associates", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013", 
        "why_stopped": "FDA requested amendment to protocol. Waiting for approval of Informed Consent script by\n    site(s) prior to resuming retrospective enrollment."
    }
}